Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

While mRNA vaccines represent a transformative platform for infectious disease control, their efficacy in antigen-presenting cells (APCs) remains vulnerable to endogenous regulatory networks, ...

PASADENA, CA, USA I April 26, 2025 I GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform that ...

Discover a study where researchers have discovered a myeloid-derived antigen-presenting cells population essential for peripherally induced regulatory T cells.

Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new ...

Our body's own defense system not only clears away bacteria and viruses, it can also fight cancer. However, not all tumor ...

New hope: MHH researchers are mobilising the immune system's defence against tumour cells within just two weeks using a two-phase vaccination regimen.

Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...

A breakthrough in preclinical data puts CK Life Sciences at the forefront of next-gen immuno-oncology. Abstract 853: ...

T-cell activation involves two phases, enabling a more precise immune response. This insight may boost cancer immunotherapy ...

A new study led by researchers at NYU Langone Health has revealed that a special group of cells found in mouse intestines ...